Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Verve Therapeutics Inc (VERV)

Verve Therapeutics Inc (VERV)
5.24 x 3 5.32 x 3
Post-market by (Cboe BZX)
5.25 +0.47 (+9.83%) 04/22/25 [NASDAQ]
5.24 x 3 5.32 x 3
Post-market 5.24 -0.01 (-0.19%) 18:03 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
4.78
Day High
5.31
Open 4.80
Previous Close 4.78 4.78
Volume 4,015,705 4,015,705
Avg Vol 5,233,271 5,233,271
Stochastic %K 68.25% 68.25%
Weighted Alpha -33.88 -33.88
5-Day Change +1.13 (+27.43%) +1.13 (+27.43%)
52-Week Range 2.86 - 9.31 2.86 - 9.31
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 424,445
  • Shares Outstanding, K 88,796
  • Annual Sales, $ 32,330 K
  • Annual Income, $ -198,710 K
  • EBIT $ -229 M
  • EBITDA $ -234 M
  • 60-Month Beta 1.86
  • Price/Sales 12.61
  • Price/Cash Flow N/A
  • Price/Book 0.79

Options Overview Details

View History
  • Implied Volatility 126.46% ( -87.11%)
  • Historical Volatility 139.14%
  • IV Percentile 73%
  • IV Rank 14.53%
  • IV High 651.57% on 04/10/25
  • IV Low 37.16% on 05/21/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 2,146
  • Volume Avg (30-Day) 1,139
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 11,139
  • Open Int (30-Day) 7,326

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.71
  • Number of Estimates 4
  • High Estimate -0.56
  • Low Estimate -0.77
  • Prior Year -0.59
  • Growth Rate Est. (year over year) -20.34%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.86 +83.57%
on 04/09/25
Period Open: 5.55
5.99 -12.35%
on 03/24/25
-0.30 (-5.41%)
since 03/21/25
3-Month
2.86 +83.57%
on 04/09/25
Period Open: 7.80
9.31 -43.58%
on 02/18/25
-2.55 (-32.69%)
since 01/22/25
52-Week
2.86 +83.57%
on 04/09/25
Period Open: 6.91
9.31 -43.58%
on 02/18/25
-1.66 (-24.02%)
since 04/22/24

Most Recent Stories

More News
Why Verve Therapeutics Zoomed 40% Higher This Week

Good news from the laboratory and a clutch of bullish analyst notes were the drivers behind Verve Therapeautics ' (NASDAQ: VERV) big stock price leap this week. By the time the dust cleared, the biotech...

BMO : 94.10 (+1.95%)
JPM : 235.59 (+2.88%)
VERV : 5.25 (+9.83%)
Why Verve Therapeutics Is Skyrocketing Today

Verve Therapeutics (NASDAQ: VERV) stock is seeing explosive gains Tuesday. The biotech company's share price was up 24.5% as of 12:30 p.m. ET and had been up as much as 41% earlier in the session.

NFLX : 1,040.34 (+5.31%)
NVDA : 98.89 (+2.04%)
VERV : 5.25 (+9.83%)
Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

VERV : 5.25 (+9.83%)
Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

VERV : 5.25 (+9.83%)
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

VERV : 5.25 (+9.83%)
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

SLDB : 3.43 (+13.20%)
CLYM : 1.2800 (+4.07%)
IMU.AX : 0.024 (unch)
LENZ : 25.79 (+6.97%)
ABOS : 0.9800 (-7.55%)
VERV : 5.25 (+9.83%)
Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose

VERV : 5.25 (+9.83%)
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

VERV : 5.25 (+9.83%)
Verve Therapeutics: Q4 Earnings Snapshot

Verve Therapeutics: Q4 Earnings Snapshot

VERV : 5.25 (+9.83%)
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

VERV : 5.25 (+9.83%)

Business Summary

Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's lead product candidate includes VERVE-101. Verve Therapeutics is based in CAMBRIDGE,...

See More

Key Turning Points

3rd Resistance Point 5.98
2nd Resistance Point 5.64
1st Resistance Point 5.45
Last Price 5.25
1st Support Level 4.92
2nd Support Level 4.58
3rd Support Level 4.39

See More

52-Week High 9.31
Fibonacci 61.8% 6.84
Fibonacci 50% 6.08
Fibonacci 38.2% 5.32
Last Price 5.25
52-Week Low 2.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro